Metastatic Castration Sensitive Prostate Cancer (mCSPC) Clinical Trials in Anderlecht, Bruxelles-capitale, Région de

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.